Compared with an active control regimen, the regimen with EMEND provided superior and sustained efficacy in highly emetogenic chemotherapy
More patients on the regimen with EMEND remained free of vomiting on Days 1 through 5 as compared with those on an active-control regimen (P<0.001).
- A second trial (N=524) showed similar results.
- See single-cycle results for patients on moderately emetogenic chemotherapy
The efficacy of the regimen with EMEND was maintained through the 6 cycles of
chemotherapy studied
- A second trial showed similar results.
- See multiple-cycle results for patients on moderately emetogenic chemotherapy
Selected Important Risk Information
The efficacy of hormonal contraceptives may be reduced during coadministration with EMEND and for 28 days after the last dose of EMEND. Alternative or backup methods of contraception should be used during treatment with EMEND and for 1 month after the last dose of EMEND.
Chronic continuous use of EMEND for prevention of nausea and vomiting is not recommended because it has not been studied and because the drug interaction profile may change during chronic continuous use.
Coadministration of EMEND with warfarin may result in a clinically significant decrease in international normalized ratio (INR) of prothrombin time. In patients on chronic warfarin therapy, the INR should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of EMEND with each chemotherapy cycle.
Before prescribing EMEND or EMEND for Injection, please read the Prescribing Information. The Patient Information also is available.
For information about Merck products or services, please call 866-448-7590. The Merck National Service Center will be pleased to assist you Monday through Friday from 8 AM to 7 PM ET.
